Merck KGaA (MRK) Earnings Call Transcript & Summary
August 7, 2025
Earnings Call Speaker Segments
Operator
operatorGood day, ladies and gentlemen, and welcome to the Merck Investor and Analyst Conference Call covering the second quarter of 2025. <<operator_script>> At this point, I'll pass things along to Florian Schraeder, our Head of Investor Relations, who will guide everyone through today's conference. Over to you, sir.
Florian Schraeder
executiveThanks so much, Heidi, and a very warm welcome to Merck’s Q2 ’25 Results Call. I’m Florian Schraeder, Head of Investor Relations at Merck. It’s a pleasure to have with us today Belen Garijo, our Group CEO; and Helene von Roeder, our Group CFO. Joining us for the Q&A portion of this call will also be Jean-Charles Wirth, CEO Life Science; Danny Bar-Zohar, CEO of Healthcare; and Kai Beckmann, CEO Electronics. During the first few minutes, we’ll walk you through the presentation’s key slides. After that, we’ll be happy to take your questions. With that, I’d like to turn things over to Belen to get us started.
Belén Garijo López
executiveThank you, Florian. Good to have everyone with us on our Q2 earnings call. Before I get into the quarter's highlights, I'm glad to remind you all that we announced last week the completion of the Surface Solutions divestiture. With this transaction now closed, we can sharpen our focus on high-tech applications within electronics. So that's a significant milestone we've recently achieved. And it comes only 1 month after we closed the SpringWorks acquisition in record time, which immediately accelerates health care growth and secures the sustainability of our health care pillar over the mid- to long term. So we are actively working on and executing our portfolio composition to enhance Merck's position as a globally diversified science and technology company with attractive growth. Turning back to the quarter, I'm now on Slide 5 of the presentation to walk through the highlights. The global economic landscape kept changing very rapidly this quarter, creating some volatility across various business sectors and regions. We continued to sustain our organic sales growth momentum in this challenging environment, even though these economic conditions are also affecting some of our business sectors to a certain extent. Organically, our group sales rose by 2% and EBITDA pre was up by 5%.
Belén Garijo López
executiveSo because of that, we kept expanding profitably on an organic basis. The strongest organic sales growth came from Healthcare and Life Science, each at 4%, whereas Electronics sales declined organically by minus 6%, mainly because of the DS&S business. The standout in the quarter was how the organic sales growth momentum in Life Science accelerated. That acceleration comes from Process Solutions, which again posted 11% against tougher comparables. Order intake growth remained very strong, and the book-to-bill ratio once more stood comfortably above 1. Organic sales in Healthcare rose 4%, fueled by double-digit growth from Mavenclad, a solid 5% increase in our CM&E portfolio, and double-digit growth from Erbitux as well. Turning to Electronics, we saw an organic decline of 6%, chiefly due to our DS&S delivery systems and service business inside Semiconductor Solutions, which saw a drop in the low to mid-double digits tied to large project phasing. Semiconductor materials kept growing this quarter, powered by our strength in artificial intelligence and advanced nodes. Now to our guidance. We are narrowing our organic sales growth range to plus 2% to plus 5%, which remains inside the range we previously communicated -- the range we communicated.
Belén Garijo López
executiveReported sales have been restated mainly to capture the currency effect. In addition, we're holding the midpoint of our absolute EBITDA pre guidance range even with mounting FX headwinds and even with adverse portfolio impacts stemming from the SpringWorks acquisition and from the divestiture of Surface Solutions, since we've raised our organic growth outlook for EBITDA pre to plus 4% to plus 8%. As a result, we now expect net sales between EUR 20.5 billion and EUR 21.7 billion, with EBITDA pre from EUR 5.9 billion to EUR 6.3 billion. So we're committed to delivering profit growth that outpaces what we previously projected. I'll share further specifics regarding the assumptions behind this guidance near the end of today's call. Let's move to Slide 6 now for a look at how each business sector performed. Organic sales growth for the second quarter came in at 2%, plus 2%. Life Science contributed the most this quarter, posting organic sales growth of 3.7%, once again powered by the outstanding results of Process Solutions. Healthcare grew 3.6% organically, with Mavenclad, our CM&E portfolio and Erbitux serving as the main growth engines. Electronics declined by minus 5.6% organically, because growth in semi materials could not compensate for the drop in our DS&S business.
Belén Garijo López
executiveSo for the group, just as we had predicted, FX became a headwind in Q2 — minus 4.2% — after being a slight tailwind in Q1 2025. Across all business sectors, FX was a mid-single-digit percentage headwind during the quarter. Along with a portfolio effect of plus 0.4% for the group in Q2, mainly from the Unity-SC acquisition, group sales — reported group sales — declined by minus 1.8% in Q2. One important point: we closed the SpringWorks acquisition on July 1. So there are no SpringWorks revenues in Q2. On earnings, EBITDA pre came to EUR 1.462 billion, growing organically more than twice as fast as sales and delivering plus 4.6% organic growth versus the year earlier period. Currency also weighed on EBITDA pre, and more strongly than on sales, at minus 7.2%. The portfolio effect was slightly dilutive on EBITDA pre. With that, let me hand it over to Helene for a more detailed review of the Q2 financials.
Helene von Roeder
executiveThanks so much, Belen, and hello from me as well. I'm on Slide 8 now, which gives an overview of the key figures for the second quarter. Net sales fell 1.8% to EUR 5.255 billion, with FX acting as a headwind of minus EUR 227 million. Portfolio effects gave a slight tailwind in Q2, at plus EUR 23 million. EBITDA pre came in 3.1% lower at EUR 1.462 billion; while EBITDA pre rose 8.8% year-on-year in Healthcare, it fell by minus 1.3% in Life Science and by 47.6% in Electronics. The drop in EBITDA pre in Electronics was primarily attributable to 2 nonrecurring items that we recognized in our second quarter results, along with foreign exchange headwinds. I'll share more details later in the presentation. FX was a stronger headwind on EBITDA pre than it was on sales, while portfolio effects had a slightly dilutive impact on EBITDA pre. EPS pre declined 8.2% to EUR 2.02 per share. The fall in EPS pre was larger than that in EBITDA pre, which was primarily driven by a more negative financial result. That, in turn, was mainly due to tax items in the financial results amid lower interest income, which in turn reflected lower cash balances.
Helene von Roeder
executiveCash flow from operations fell to EUR 567 million. That drop came primarily from bigger tax and bonus outlays. Net financial debt rose by EUR 818 million versus the end of December '24, and that reflects the dividend payment we made. Let me also give a quick comment on our reported results. With that, I'm now on Slide 9. EBIT rose 12.4% year-on-year. That gain exceeded the EBITDA pre increase, largely because D&A came down from a high level in Q2 '24. As a reminder, we booked the impairment on Xevinapant in Q2 of last year. The financial result dropped sharply by minus EUR 55 million, moving from minus EUR 7 million to minus EUR 62 million, driven mainly by a more negative interest result. That reflects tax items as well as lower interest income on a reduced cash balance. The effective tax rate was 21.0%, which sits at the low end of our 21% to 23% guidance range and below the 22.9% effective tax rate from the prior-year period. The tax rate typically moves around from quarter to quarter during the year. For the first 6 months of '25, our effective tax rate is 21.9%, right in the middle of our tax rate guidance.
Helene von Roeder
executiveJust to remind everyone, this year brings extra uncertainty given all the discussions surrounding taxes and tariffs. Reported EPS was EUR 1.50, up 7.1% year-on-year, and that sits below EBIT growth because it mirrors weaker financial results relative to the same period a year ago. With that said, let's proceed to the sector review, beginning with Life Science on Page 10. Life Science posted organic growth of plus 3.7% in Q2. That marks yet another acceleration versus the prior quarter, as Process Solutions held onto its momentum while Science & Lab Solutions demonstrated improving momentum. So let's begin with Process Solutions. Organic sales rose 11.5% in the second quarter. It thus preserved the growth momentum carried over from the prior quarter, which is now measured against a growing base. Customer destocking is at last behind us. Order intake kept growing very strongly, and book-to-bill stood at levels similar to the last 2 quarters, remaining comfortably above 1. No meaningful preordering effects showed up in Q2 '25. Let's now examine Science & Lab Solutions more closely. Organic sales were flat.
Helene von Roeder
executiveAlthough shifts in U.S. policy keep weighing on academic and government lab spending, we did observe some green shoots among our pharma and larger biotech customers. We feel increasingly comfortable moving toward our midterm growth aspiration of low single-digit to mid-single-digit organic growth in Science & Lab Solutions by Q4 of this year. In Life Science Services, sales declined 8.2% organically, driven primarily by a decline of roughly a low teens percentage in our Contract Testing Services business amid demand fluctuations from key customers. In addition, Q2 '25 faced the highest comparison base from '24. Our CDMO business was organically up this quarter, excluding a sales effect tied to the disposal of the <<inaudible>> site, which was closed on August 1. EBITDA pre rose 3.7% organically in Q2, in line with organic sales growth. Positive operating performance and mix effects were offset by production cost phasing. While our EBITDA pre margin was flat year-on-year on an organic basis, both FX and portfolio effects were dilutive. With that, I'm now on Slide 11 for an overview of how the Healthcare business sector performed. Healthcare once again delivered solid organic sales growth of 3.6% in Q2, which is very similar to what we actually saw in Q1.
Helene von Roeder
executiveTurning to franchise performance, CM&E stood out as the biggest growth driver within Healthcare. Organic growth came in at 4.7%, matching our medium-term ambition of a mid-single-digit CAGR. Every therapeutic area posted organic growth. In Oncology, organic growth reached 3.9% for Q2, with Erbitux up 10.9% organically and Tepmetko ahead 41.4%, which more than made up for the expected drop in Bavencio — that product fell minus 12.1% in Q2 amid a competitive environment. Erbitux growth came from nearly every region, though China showed slowing. Tepmetko's gains were driven largely by very strong demand in North America and APAC, helped by a distribution agreement signed recently. Our N&I franchise posted 2.6% organic growth in Q2. Rebif declines, consistent with the interferon market, were more than offset by Mavenclad, which delivered stellar organic growth of 20.7%. North America was the main driver there, aided by a favorable channel mix. Fertility sales declined minus 3.4% in Q2, facing still elevated comps that reflected competitor stock-outs in the prior year, along with a slightly softening market. On the pipeline side, full results from Part 1 of the Phase III MANEUVER study were presented at the ASCO Annual Meeting, demonstrating that pimicotinib achieved significant improvement in objective response rate versus placebo at the primary endpoint as well as across all key secondary endpoints.
Helene von Roeder
executiveMerck owns the global commercialization rights for pimicotinib, and we plan to bring it to market in 2026. In addition, at ASCO we shared Phase Ib results for M9140, whose efficacy and safety support further development of this anti-CEACAM5 ADC. Strong organic sales growth in Q2, together with temporarily reduced R&D spending and a favorable mix, helped us reach an EBITDA pre margin of 37.2% for the quarter. Versus the same quarter a year ago, our EBITDA pre margin rose by 350 basis points, which implies organic growth of plus 20%, partly reflecting a soft comp that included a mid-double-digit million euro R&D impairment last year. In total, EBITDA pre came to EUR 783 million in Q2. Regarding how our R&D spending will evolve further, let me remind you that we anticipate underlying R&D costs rising gradually across the coming quarters, both in absolute terms and as a percentage of sales. With SpringWorks added on top, we expect the R&D ratio in H2 to be around 20% of sales. So let us turn to Electronics on Slide 12. On an organic basis, sales fell by minus 5.6% in Q2, as Semiconductor Solutions declined by 5.6% organically. The main driver is the performance of our DS&S business within Semiconductor Solutions, which dropped by more than 30% organically in Q2.
Helene von Roeder
executiveIn the quarter, semiconductor materials kept expanding, posting a low single-digit rate against tougher comparisons. After the Surface Solutions divestiture, this unit now represents roughly 2/3 of Electronics sales. Even so, it couldn't counterbalance the sharp drop in our DS&S business during Q2, where customers told us projects have been delayed even further. Growth in semiconductor materials is still being propelled by AI and advanced nodes. Still, a near-term rebound across the broader market—particularly NAND and memory—remains out of view. Organically, Optronics fell 5.3% in Q2, yet on a reported basis it edged up plus 0.3%, helped by the consolidation benefit from Unity-SC. Surface Solutions declined minus 6.4% organically, largely on softer cosmetics demand. You've likely seen our announcement that the Surface Solutions divestment closed on July 31. As a result, Q2 marked the final quarter in which we fully consolidate Surface Solutions. The organic drop of minus 41.3% in the EBITDA pre margin during Q2 reflected 2 special onetime effects. The first was a onetime noncash adjustment to a PPA entry tied to manufacturing know-how from the 2014 acquisition of AZ Electronic Materials, totaling a low double-digit million euro amount.
Helene von Roeder
executiveThis line correctly captures the fact that the know-how tied to the initial PPA entry has reached the end of its useful life, and it does not represent how our operations are performing on an ongoing basis. On top of that, we booked a provision in the mid-double-digit million euros for customer compensation stemming from a historical supplier mislabeling that led to a pricing issue. There were no quality concerns, and the customer relationship remains strong, with orders continuing. We are pursuing appropriate remedies. Together, these two items dragged down our EBITDA pre margin in Electronics by roughly minus 7 percentage points. Beyond that, other factors — chiefly the substantial downturn in our DS&S business and FX — cut the margin by a further approximately 4.5 percentage points. All told, EBITDA pre margin came in at 15.1% for the quarter, which works out to an EBITDA pre of EUR 134 million. As for how the margin will move over the rest of '25, please keep in mind that we divested Surface Solutions, which had a margin-dilutive effect on Electronics. I'd also like to emphasize that the 2 special effects just described, recorded in our Q2 results, were confined to Q2 and will not repeat. Before I hand things back to Belen, let me also offer a brief comment on our balance sheet and cash flow statement. As Slide 13 shows, our balance sheet was down by EUR 4.2 billion relative to the end of December 2024.
Helene von Roeder
executiveLet's dig a bit deeper into the asset side. Our cash and cash equivalents fell to EUR 1.2 billion, down from EUR 2.5 billion at the close of December '24, and the reason was repayment of a U.S. dollar bond that happened in March of this year. Inventories held steady, whereas receivables rose by EUR 300 million, coming after a quarter of robust cash collection at the end of last year. Property, plant and equipment declined by EUR 300 million, driven mostly by FX translation differences. Intangible assets dropped by EUR 2.6 billion, reflecting FX effects and D&A. Finally, other assets came down by EUR 300 million, largely on divestments and revaluation effects. Now moving over to the liability side. Financial debt fell by EUR 900 million, which mirrors the U.S. dollar bond repayment in March this year. That was partly offset by a reduction in other liabilities, which in turn was impacted by dividend payments in Q2. Pension provisions declined, pushed by actuarial gains. Payables went from EUR 3.1 billion to EUR 2.9 billion, as we recorded decreases in current payables across all 3 of our business sectors. And net equity was lower by EUR 1.7 billion, since the rise in retained earnings was more than offset by FX differences, chiefly stemming from the weakening of the U.S.
Helene von Roeder
executiveIn summary, our equity ratio improved further, moving from 58% at December 2024's end to 60% at the close of Q2. It did slip a bit from 61% at the finish of Q1 this year after the annual dividend was paid. Now turning to cash flow on Slide 14. Operating cash flow fell from EUR 861 million in Q2 of last year to EUR 567 million in Q2 '25. The main reason was changes in other assets and liabilities, which were driven in turn by larger bonus payouts and tax cash outs during the quarter. The rise in tax cash-outs largely reflects the phasing of a tax payment in Switzerland, which took place in Q2 of this year rather than Q3 of last year. D&A saw a notable year-on-year decline this quarter, primarily attributed to the absence of last year's EUR 140 million impairment tied to Xevinapant and a decrease in amortization of acquired intangibles. That reduction is not entirely reflected in the increase in profit after tax, due largely to a year-on-year decline in financial results and significant currency headwinds that hit our sales and, in return, profits. Cash-out for investing activities rose by EUR 113 million, which mainly reflected the payment to Abbisko for global commercialization rights to pimicotinib.
Helene von Roeder
executiveFinally, one more item: financing cash flows differed because of proceeds from short-term investments during the quarter. With that said, I’ll turn it back to Belen for the outlook.
Belén Garijo López
executiveOkay. Thank you, Helene. Let's move on now to the updated guidance we have on Slide #16. Looking back at what I said earlier about currency effects, we've now built in a larger FX headwind, which comes as no surprise. For group net sales, we are now accounting for an expected currency drag of minus 5% to minus 2%. As a result, we are changing our 2025 reported corridor for group net sales to a range of EUR 20.5 billion to EUR 21.7 billion. Our guidance for organic net sales growth is plus 2% to plus 5%, which remains, as I mentioned earlier, inside the range we communicated previously. Now turning to EBITDA pre: even with the growing FX headwinds, and the estimated negative portfolio effects of minus EUR 120 million to minus EUR 80 million stemming from the SpringWorks acquisition and the Surface Solutions divestment, we are keeping the midpoint of our absolute EBITDA pre guidance and narrowing the range to EUR 5.9 billion to EUR 6.3 billion. We have also lifted our organic growth corridor for EBITDA pre to plus 4% to plus 8%, up from plus 2% to plus 7%. In addition, even with SpringWorks included, we are guiding for an EPS pre range of between EUR 8 and EUR 8.70, lowering the midpoint only slightly, by EUR 0.10.
Belén Garijo López
executiveWhen it comes to tariffs, our guidance reflects their full impact as we understand things today. For more detail broken out by business sector, please turn to Slide #17. Beginning with Life Science, we're raising our organic sales growth guidance and now expect a range of plus 3% to plus 6% for 2025, tilted toward the upper half of the prior corridor. We anticipate Process Solutions will already reach the midterm target in 2025, a CAGR of roughly 10% growth. For EBITDA pre, we expect organic growth of between plus 3% and plus 7%, which adjusts and lifts the lower half of our guidance range. That upgrade is consistent with our narrowed top line guidance, and we're confident about delivering an improvement in organic EBITDA pre margins in 2025, as the midpoints of our guidance ranges indicate. Turning to Healthcare. Our guidance for organic sales growth is being narrowed to a range of plus 3% to plus 5%, with the midpoint unchanged. The key contributors to this organic sales performance remain our CM&E portfolio, Mavenclad and Erbitux. We also expect portfolio effects to contribute to net sales to the tune of EUR 170 million, stemming from the acquisition of SpringWorks.
Belén Garijo López
executiveWe're happy with how SpringWorks performed in Q2. Sales of Ogsiveo reached USD 67 million for the quarter — a 52% increase quarter-on-quarter and the best quarter since launch — while Gomekli brought in USD 15 million in sales during the quarter. We're raising our guidance for EBITDA pre organic growth to plus 9% to plus 13%, driven by strong leverage growth together with disciplined cost management and the divestment of an FDA priority review voucher, which we agreed at the end of July and which affects the earnings of the healthcare business sector by a mid-double-digit million euro amount in the second half of the year. For Electronics, we're lowering our forecast for organic sales growth to a range of minus 5% to minus 1%, and this mainly reflects further delays in customer projects that are now moving beyond 2025, affecting our DS&S business. Although we expect Semi Materials to deliver continuous growth in 2025, that growth won't offset the anticipated decline in our DS&S business. DS&S phasing, along with the nonrecurring one-timers from Q2, has led to reduced expectations in our organic growth guidance for EBITDA pre, which we now expect to be in a range of minus 15% to minus 7%.
Belén Garijo López
executiveAlthough it wasn't part of the guidance update I just walked through, I'd also like to point out that we've lowered our corporate and other EBITDA pre guidance from EUR 500 million to EUR 550 million down to EUR 350 million to EUR 400 million. The main reason for this change is hedging gains, and it also reflects a mid-double-digit euro million onetime effect caused by regulatory changes in Latin America. All in all, Q2 was a robust quarter, and once again we achieved profitable organic growth even as the macroeconomic backdrop stayed challenging throughout. In addition, we completed 2 major strategic milestones, the closing of SpringWorks and Surface Solutions, and we remain highly confident that we will deliver even stronger profitable organic growth in 2025 than we previously expected. With that, thank you very much for your attention, and we'll be glad to begin taking your questions. Florian, over to you.
Florian Schraeder
executiveAppreciate it, Belen and Helene, for walking us through the slides. At this point I'll hand things over to Heidi, and she'll run the Q&A portion of the call.
Operator
operator<<operator_script>> Our initial question is from Sachin Jain of Bank of America.
Sachin Jain
analystI’ve got one question per division, if I may. First, on Electronics: can you say anything about how long those delayed projects within DfS are being pushed out? In other words, how long should we factor in that effect? And could you add a little more detail on the wider macro picture, where you said a recovery is not in sight? I’m just trying to understand what forward visibility you have, and so any initial views on ’26 as well. On Healthcare, I’d like your thoughts on the Mavenclad IPR result and how that might affect the ’25 guidance. And third, on Process, any comments on growth rates as we exited 2Q and on July trends? Some industry commentary has pointed to softer conditions more recently. It doesn’t seem like you’re seeing that, but I just wanted to check.
Belén Garijo López
executiveThanks, Sachin. Electronics is where we'll begin with Kai.
Kai Beckmann
executiveYes. Sachin, it's Kai here. Thank you for asking about electronics. Regarding DS&S, we'll provide an update as soon as we have better visibility on when those projects will begin — restarting once implementation resumes. At present, for the second half, we included only what was genuinely locked in and confirmed following last quarter's discussions, taking a very cautious approach so as not to overstate what may unfold in '25. So let's examine what could then take place in '26. Stepping back to the bigger picture, Sachin. By year-end, Electronics will have taken shape, with the portfolio focused solely on Electronics businesses. Surface is no longer part of it. Unity becomes fully included starting in November. We will be a sector dedicated exclusively to the electronics industry. On the materials side, you'll see growth at a high single-digit rate. That's what our guidance reflects and what we anticipate. That represents 2/3 of our portfolio. So 80% of electronics is semi, and 80% of semi is materials. Thus 2/3 being materials, growing at that rate. And market projections give no signal that would diverge from what we expected previously. Where materials are concerned, that remains well intact as we head into 2026.
Danny Bar-Zohar
executiveSachin, this is Danny. On the IPR question: first of all, our confidence in the LOE base case we gave for Mavenclad — October 2026 — remains very strong. And in fact, on July 11 there was a Court of Appeals for the Federal Circuit hearing, and after hearing what took place there — just listening to the discussion — I'd say it keeps our confidence in October 2026 rather high. You also brought up the 2025 forecast. You saw the stellar growth for Mavenclad in the second quarter. For the full year, we expect something similar to last year — double digit, low to mid-teens. And even in the highly unlikely scenario for us that generics hit us, the impact, I'd say, would be super limited and well within our guidance.
Jean Wirth
executiveAnd Sachin, this is Jean-Charles. We're not sharing any Process Solutions results for July. That said, I can say we expect solid performance from Process Solutions in 2025. And at this point we feel very confident about hitting our midterm organic growth aspiration — a CAGR of roughly 10% for this year.
Operator
operatorOur next question will be taken now, and it comes from the line of Sophia Graeff Buhl Nielsen at JPMorgan.
Sophia Graeff Buhl Nielsen
analystTwo questions on Life Science. First, for SLS, how did U.S. academic and government do in Q2 compared with what you initially expected? And how should this segment perform over the remainder of the year and as we go into 2026? Then one on Process Solutions: what drove the very strong order intake you saw this quarter? Has it picked up sequentially? And do you expect book-to-bill to stay above 1 for the rest of the year?
Jean Wirth
executiveThanks, Sophia. Jean-Charles here. I'll begin with the SLS question, then move on to PS. Let me say right off that conditions in our lab market right now are definitely tough. I'd like to offer an illustration. You brought up the U.S. — yes, our academic customers are still holding back because of the significant uncertainty tied to policy changes in the U.S. That said, I'd also ask you and everyone on the call to remember that our NIH exposure is limited, at about 10% of our portfolio. Still, it's fair to say Q2 took a hit in the U.S. And on top of that — when I talk about shifting market conditions, I also want to point to China. China is still muted. I'd also like to flag how some pharma customers are behaving: they keep watching their spending very closely, particularly when it comes to early research activities. That said, we do expect pharma discovery to recover gradually before long. I'll also echo what Helene said: we're seeing green shoots among certain customers in 2025 in Q2, and we're also seeing some positive movement in pharma quality control. So that's the situation we're facing.
Jean Wirth
executiveEven so, we've kept right on executing against our strategy, and I'd like to give you 2 specific examples. The first concerns innovation. Earlier this year, we announced that we were acquiring Hub Organoids. And at this point, we're bundling Hub Organoids together with our <<inaudible>>, a cutting-edge tool that enables rapid and objective measurement of cell cultures. And I'd say the initial sentiment we're hearing from customers has been extremely positive. Another illustration of how we're executing on strategy involves our multi-omnichannel approach. We sell via our direct sales force, through our dealers and through e-commerce. And yes, we're making solid strides. So if you put the present market situation together with our very clear strategy and execution, we're doing quite well in the market, I'd say. In Q2, we were flat. And I'd like to point out that I view the SLS business as highly resilient. So going forward, by year-end we expect to deliver organic growth toward our midterm guidance in SLS of low single to mid-single digits. Now let me turn to Process Solutions. On Process Solutions, you asked about order intake. First of all, I'd like to take this chance to note that during the last months, we've, let's say, enhanced the quality of our reporting when it comes to order intake.
Jean Wirth
executiveWhen it comes to tracking processes, we've reached a point where we can locate any kind of information tied to our order intake, and we can slice and dice that information by customer, region, portfolio, and so on. So we're fairly confident in the quality of our data. To address your question, we don't see any order pull-in during Q2. We're also confirming, and we believe, that customer destocking now lies behind us. And regarding your final question about the book-to-bill ratio, we're comfortable having a book-to-bill ratio above 1. That was the case in Q4 2024. It was the case in Q1 2025, and it remains the case in Q2 2025. So overall for Process Solutions, as I mentioned earlier, we're now comfortable and confident about reaching our midterm guidance for the full year of around 10%.
Operator
operatorThe following question is from Matthew Weston at UBS.
Matthew Weston
analystTo pick up where the previous question left off regarding bioprocess demand — Jean-Charles, I believe you addressed this, but let me make sure it's crystal clear. Given the fresh visibility you now have into your customers, do you feel confident they aren't speeding up manufacturing in anticipation of U.S. tariffs? In other words, are we essentially looking at a pull forward that will show up as a slowdown next year, and that what we're seeing is genuinely sustainable growth? And would you truly have that level of visibility? Then for the second one, I'm not sure if this is for Danny or Helene. Setting aside the timing debate from Sachin's question, Mavenclad's U.S. patent expiry is coming soon. Most of us would assume a $45,000 small molecule is extremely profitable, but I'm aware there's also a neurology sales force attached to it. So could you help us understand how Mavenclad's relative profitability in the U.S. compares with your normal health care margins, so we can plan for the midterm and the gradual loss of Mavenclad in the model?
Jean Wirth
executiveMatthew, it's Jean-Charles here. So, briefly: our confidence in the quality of order intake is high. And just to give you a sense of it — in Q2, I mentioned that we hadn't observed any pull forward at the global level. Our information is detailed enough that in early April we did see some in China, yet at the global level that value was negligible. So on the whole, the main takeaway is: yes, we are confident.
Danny Bar-Zohar
executiveMatthew, Danny here. On that Mavenclad question: to repeat what I said earlier, our base case has October 2026 as the U.S. loss of exclusivity, with a staggered European timeline running from summer 2027 through 2030, depending on SPCs country by country. So the global decline won't be abrupt. That's the first point. When that decline does arrive, it will be profitable. We'll manage it. As a reminder, we're also building sales forces for SpringWorks both in the U.S. and outside it, and that will be handled properly.
Operator
operatorFalko Friedrichs with Deutsche Bank has the next question.
Falko Friedrichs
analystStarting with Process Solutions as well — can you add some detail about how orders and sales moved for consumables compared with equipment during the latest quarter? Second, regarding your group guidance, did the tariff assumptions baked in change at all from the initial guidance given with Q1? And third, a quick one for Kai: could you shed a bit more light on precisely what that labeling issue involved?
Belén Garijo López
executiveI'll begin with the group guidance, just to confirm that everything we currently have in hand is reflected in that guidance, and that nothing significant has changed compared with what we shared in Q1.
Jean Wirth
executiveOn Falko's first question, Jean-Charles here — at a very high level, looking at our portfolio as it stands, about 90% — that's 9-0 — of what we have in Process Solutions is driven by consumables.
Kai Beckmann
executiveYeah, Falko, regarding the electronics question — so what happened is a supplier mislabeled some products, and that caused customers to be overcharged across the past 15 years. We've since compensated them for that, and at this point we're pursuing remedies against that supplier for the damage.
Falko Friedrichs
analystAlright, just a quick follow-up on the Process Solutions question. Could you give us a bit more detail on the equipment piece — that 10% portion — in terms of what you're seeing on demand and orders?
Jean Wirth
executiveIt's quite limited, Falko, honestly. That number really is small. Like I mentioned before, most of what we have in the portfolio right now is tied to consumables.
Operator
operatorOur following question is from Charles Pitman-King of Barclays.
Charles Pitman
analystCharles Pitman-King from Barclays. Just a quick one to kick things off regarding your corporate and other EBITDA pre-guidance. I was wondering whether you might share a bit more detail about what those local regulation changes actually are and whether you can give us any further quantification around that mid-double-digit impact. Then secondly, on the Ogsiveo outlook. So within the desmoid tumor space, I was wondering if you could speak a bit about what you expect for potential competition, given competitors such as AL102, which so far has apparently shown superior Phase II data and is set to report Phase III in 2H '25. Just wondering how you're thinking about Ogsiveo's likely treatment position should AL102 outperform its data?
Helene von Roeder
executiveRegarding the regulation, what I can tell you is that it's similar to the situation in Latin America. The law has changed, and that change has affected our entire sector, which explains why you're seeing this effect in the corporate line.
Danny Bar-Zohar
executiveDanny here. Thanks for asking about Ogsiveo. First off, we're extremely excited — as Belen mentioned at the start — about the fairly quick closing of the deal on July 1, and you've seen the second-quarter figures, which are extremely strong. Right now we're seeing very high and sustained demand for the drug, and that leaves us very, very encouraged by how it's performing, especially in the U.S., which is where it's launched at present. On competition, and to give you a bit of guidance on the challenges and the market: you brought up AL102, and of course we factored it in from the earliest days of our due diligence, and the commentary we've heard comes largely from its Phase II data in what I'd call a much limited number of patients. With all that said, one point I personally believe is important to leave you with is that we take AL102 super seriously. Why? Because it shares the same mechanism of action as Ogsiveo, and so we expect it to work. I also want to draw a distinction between what all of us know about the compound and how seriously we're already treating it when it comes to educating our field teams, building scenarios, shaping the market, and on top of that, how we modeled it into our assumptions.
Danny Bar-Zohar
executiveSo clearly, we can't share with you the specific inputs we used in our assumptions, but keep in mind that this is also the prevalent population — roughly those 30,000 patients in the U.S. — with substantial potential to serve people who right now are stuck in limbo between watch and wait and a yes or no on surgery. So the potential there is substantial. And the model underlying our valuation, and the guidance we've given once we closed the deal, or once we announced the deal, for peak sales of around $1 billion, factors in the competition very seriously as well as, I'd say, a patient pool that is considerably more conservative than the 30,000. Now moving to Ogsiveo, with a hazard ratio of 0.21 on PFS, a median not reached, and a 2 years landmark of 76% progression-free, we view that as a very high bar in itself. We — and AL102, could AL102 hit 72% or 80%? Yes, of course, but it's the same class. The second point is toxicity. We've also gotten, I'd say, the thoughts or commentary regarding the potential for less ovarian toxicity with Ogsiveo. Obviously, we take that extremely seriously, because these patients need to stay on drug.
Danny Bar-Zohar
executiveThis is a chronic condition, not a malignant tumor. What I can share with you now, based on real-world discontinuation rates for any reason with Ogsiveo, is that the rate is quite low and closely mirrors what we observed in the DeFi trial, where patients increasingly learn to handle their adverse events through label-approved dose adjustments and so on. And specifically regarding ovarian and toxicity, the vast majority of those cases are reversible, whether on drug or off drug, so patients know how to manage it. So we're not taking it lightly. It's the same mechanism of action. It will work. We have a first-mover advantage. As I said, strong adoption continues across all sites of care. We're very pleased that the total number of Ogsiveo prescribers keeps growing month-over-month, and we have a strong base of physicians who've had, I would say, a very positive experience with Ogsiveo since its approval in late '23. Just to give you a bit of flavor, in the first half, centers of excellence account for approximately 1/3 of the ordering accounts and about 2/3 of the total volume, and we are expanding.
Danny Bar-Zohar
executiveWhen you grasp these figures, you can see — if you take in these figures, you can see that we are already well past where we need to be when it comes to the centers. So we're very excited about this, and we look forward to sharing more on that at the Capital Markets Day.
Operator
operatorShyam Kotadia with Goldman Sachs has the next question.
Shyam Kotadia
analystTwo questions from me, please. The first concerns Electronics. Just some color on the margin going forward. The midpoint of your full-year '25 guidance implies roughly 23%. That suggests an acceleration in the second half to about the 26% mark. What's driving that? Is it simply the removal of the lower-margin Surface business? Or is there something else underneath that you're expecting? And then how should we think about a normalized margin for Electronics going forward, excluding Surface? Will it be the exit margin of around 26%? Or might we expect it to rise going forward toward the high 20s and low 30s once you're past the negative impact of DS&S? That's the first question. The second is on SpringWorks. On the top line, based on your Healthcare portfolio-effect guidance, you've guided to roughly EUR 170 million for the second half of '25. But looking at Ogsiveo and Gomekli sales in the first half of '25, you got around EUR 80-odd million. So that implies fairly flat sequential growth quarter by quarter, and the 2 relatively new launch assets. So again, could you confirm why that is the case, especially if you mention that Ogsiveo is growing pretty well, and whether there's any volatility we should be aware of?
Kai Beckmann
executiveOn the margin question, electronics: where do we begin in Q2? You had a 7% effect from one-timers. There was a 1% currency effect, plus a fairly large mix effect, which accounts for the bridge versus the prior year — mix impact from DS&S, for the known reasons. Much of that disappears in the second half, bringing us back nearer the high 20s range. That's the path ahead. The dilution from ramp-up costs that remain on our books will ease, and naturally our very strong <<inaudible>> business will contribute positively, with favorable mix helping to bridge from today's position, driven by volume growth and faster leverage, and with that an improved margin profile toward year-end. That is what we expect for the second half.
Danny Bar-Zohar
executiveThis is Danny, on SpringWorks. As I’ve mentioned previously, we’re extremely happy with the way the Ogsiveo and Gomekli launches are going. Gomekli’s first days are progressing. Demand is very strong for both products. The EUR 170 million figure you referenced for the second half covers both products, so it isn’t just one of them—it’s the two combined. And we’ve now had that under our belts for 2 months. What we’re seeing has us very encouraged. I think our commitment to the EUR 170 million aligns very well with the month-over-month growth we discussed earlier. If there are further updates on that—and we’re working on it—we’ll provide them at the Capital Markets Day.
Operator
operatorOliver Metzger from ODDO BHF has sent in a question.
Oliver Metzger
analystThe initial 2 items concern Process Solutions, and the first is a follow-up to Falko's question. Yes, we're aware that equipment accounts for just 10% of Process Solutions. Could you nonetheless give us some sense of how demand for equipment has trended? Are we already seeing any normalization? Then, still within Process Solutions, could you discuss demand across the various modalities? And the final one is about Electronics. So on DS&S, you've spoken previously about distinct cycles, such as infrastructure coming first and fab equipping afterward. Now it appears customer orders have come to a complete stop, which technically brings to mind what happened during the financial crisis. So visibility on those orders remains quite limited. But could you describe what a recovery might look like? Does it begin with infrastructure once more? Or is infrastructure still in place, with the present halt tied more to equipment? And in that same context, how much do macro conditions matter, or what has to be satisfied before we witness a turn for the better? That's all.
Jean Wirth
executiveOliver, Jean-Charles here. I'll do my best to address the first 2 questions regarding Process. The first of those concerned our equipment. As I mentioned, close to 90% of what we have in our portfolio relates to consumables. Consequently, there isn't much on equipment that we can share with you. Regarding your second question, on demand, we are moving more in the direction of traditional modalities rather than the novel modality. So please take it that traditional sits nearer to our core business.
Kai Beckmann
executiveRegarding the DS&S question, Oliver, let me remind you about the three components of DS&S. There's our services business, which is stable to growing. Then there's the equipment business, which is essentially routine sales of new equipment for new materials. Specifically, I want to highlight the molybdenum precursor here, since it demands a very particular delivery technology — that's a crucial piece. And on top of that, we also have turnkey plus equipment business tied to large projects and certain individual large projects. In past years we saw an unusual volume of large project business, which pushed that business to a significant peak, and now it's essentially returning to normal levels. And here, we had a very short notice period on the substantial delays of these projects, and that is what has produced the difference in our expectation, as you can see. But the underlying business — very important to keep in mind — is important, strategically important, high tech, and also a long-term growing business.
Operator
operatorOur following question is from Simon Baker at Rothschild & Co Redburn.
Simon Baker
analystBen here, speaking for Simon Baker. I’d like to ask 2 questions, if that’s all right. First, regarding Science & Lab Solutions: has the U.S. NIH effect been smaller than anticipated, or is it still too soon to gauge the complete impact? Second, on the one-off items: it appears the EBITDA pre miss came wholly from the one-offs in Electronics. Could you give us a bit more quantification than what appears in the press release, please?
Jean Wirth
executiveJean-Charles here. I’ll do my best to address the first question about SLS. Our exposure to NIH funding is quite modest. And to tie that back to the earlier question — the one about Process Solutions hardware versus equipment, or equipment versus consumable — you should assume the split in the lab business is the same. So with that in mind, our exposure to NIH in the U.S. is limited, or modest.
Helene von Roeder
executiveOkay, let's step back and look at the larger picture for a moment, since I realize this quarter is messy and pretty tough to model. But when you examine it, it's essentially the case that we had 2 negative items this quarter, and those came from Electronics. One was low double digit, one was mid-double digit, and for some it's mid-double digit. One of those we already explained — it's essentially a reserve we had to take related to customer claims. But naturally, we will turn around and ask our supplier to compensate us for the damages. What you need to understand, of course, is that when you look at the accounting, the reserve for the customer claims has to be booked immediately, whereas the remediation from a supplier can only be booked virtually actually once the cash is in the bank. So that's the first one to focus on. And let me tell you, these are really truly nonrecurring items, basically going back more than 10 years ago. Second, then you have the upside, the positive. One is, when you look at the full year, the disposal of the PRV voucher, which also is a double-digit positive on the EBITDA side.
Helene von Roeder
executiveAnd there's that item we discussed, the corporate side over in Latin America. Both of those now land in the third quarter. On top of that, you've got the negative effect from FX once again. Adding all of it together, you arrive at a situation of plus/minus 0. Sorry, I'm speaking German. So if you then look at our EBITDA upgrade, you can actually see the strength of our business and what we've actually accomplished here, because we're additionally offsetting the downside that SpringWorks will bring into Q3 and Q4. So I hope that gives you some color on how we're viewing the situation and helps you sort through a little bit of the mess that we're seeing in Q2.
Operator
operatorDylan van Haaften from Stifel is the one asking the question.
Dylan van Haaften
analystSo I have just 2 questions. First, regarding the recent BARDA cancellations and mRNA funding—I know you have some involvement on the LNP side. I was wondering whether you're seeing any effects or downstream consequences from that. My second question concerns SLS. We've discussed academia and AH extensively. But you note that SLS is generally flat geographically. I'm curious whether what we're observing is simply broader R&D hesitancy rather than something tied to policy at this stage. Jean-Charles, I believe you mentioned expecting to land at mid-single digit by year-end. Could you offer some color on whether we might be overreading policy at this point?
Jean Wirth
executiveBack to mRNA — it's Jean-Charles again, and Dylan, thanks for the question. On that first point about mRNA spending, right now we aren't seeing a major, major impact; there's a little bit in the Labs and Services. As for the second question on SLS, you're correct. Our sales are spread quite well across geographies, let's say Americas, 1/3; EMEA, 1/3; Asia, 1/3. And at this point — as I mentioned, we expect to land the year positively. What I mean by that is we look for — we expect to deliver organic growth toward our midterm guidance of between low single digit to mid-single digits by the end of 2025. So all in all, we're quite positive. And again, we have to keep in mind that H2 has a lower base.
Florian Schraeder
executiveChecking the clock, it seems our Q&A session has wrapped up for today, and we really appreciate all the questions you sent in. At this point, I'll hand things over to Belen for a few closing remarks.
Belén Garijo López
executiveWell, I just want to say thanks to everyone for joining our Q2 call. To sum things up, we stayed on our path of profitable organic growth despite this challenging environment we're all familiar with, and we anticipate growing even more profitably than we expected in Q1 as we move through the year 2025. So we genuinely look forward to seeing many of you at the roadshows and conferences coming up. And I'd like to wrap up by wishing all of you a good summer.
Operator
operatorThank you, everyone, for joining us. That brings this call to a close. You're free to disconnect now.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Merck KGaA transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Merck KGaA earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Merck KGaA or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.